S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
How major US stock indexes fared Friday, 4/19/2024
Stock market today: Tumbling tech stocks drag Wall Street to the finish line of another losing week
American Express profits jump 34%, helped by jump in new customers, higher spending
American Express, Fifth Third rise; Netflix, PPG Industries fall, Friday, 4/19/2024
Intuitive Surgical Stock Can Trend Much Higher This Year 
3 Magnificent Seven Stocks Outperforming the Rest
Bargain Hunting: 3 Stocks With RSIs That Scream Oversold
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
How major US stock indexes fared Friday, 4/19/2024
Stock market today: Tumbling tech stocks drag Wall Street to the finish line of another losing week
American Express profits jump 34%, helped by jump in new customers, higher spending
American Express, Fifth Third rise; Netflix, PPG Industries fall, Friday, 4/19/2024
Intuitive Surgical Stock Can Trend Much Higher This Year 
3 Magnificent Seven Stocks Outperforming the Rest
Bargain Hunting: 3 Stocks With RSIs That Scream Oversold
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
How major US stock indexes fared Friday, 4/19/2024
Stock market today: Tumbling tech stocks drag Wall Street to the finish line of another losing week
American Express profits jump 34%, helped by jump in new customers, higher spending
American Express, Fifth Third rise; Netflix, PPG Industries fall, Friday, 4/19/2024
Intuitive Surgical Stock Can Trend Much Higher This Year 
3 Magnificent Seven Stocks Outperforming the Rest
Bargain Hunting: 3 Stocks With RSIs That Scream Oversold
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
How major US stock indexes fared Friday, 4/19/2024
Stock market today: Tumbling tech stocks drag Wall Street to the finish line of another losing week
American Express profits jump 34%, helped by jump in new customers, higher spending
American Express, Fifth Third rise; Netflix, PPG Industries fall, Friday, 4/19/2024
Intuitive Surgical Stock Can Trend Much Higher This Year 
3 Magnificent Seven Stocks Outperforming the Rest
Bargain Hunting: 3 Stocks With RSIs That Scream Oversold
NYSE:ZYME

Zymeworks (ZYME) Stock Price, News & Analysis

$8.85
+0.18 (+2.08%)
(As of 04/19/2024 ET)
Today's Range
$8.65
$8.98
50-Day Range
$8.67
$12.90
52-Week Range
$6.01
$13.14
Volume
1.00 million shs
Average Volume
569,595 shs
Market Capitalization
$624.54 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$15.00

Zymeworks MarketRank™ Stock Analysis

Analyst Rating
Hold
2.00 Rating Score
Upside/​Downside
69.5% Upside
$15.00 Price Target
Short Interest
N/A
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
-0.13mentions of Zymeworks in the last 14 days
Based on 3 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($1.04) to ($0.37) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

0.87 out of 5 stars

Medical Sector

809th out of 911 stocks

Pharmaceutical Preparations Industry

363rd out of 411 stocks

ZYME stock logo

About Zymeworks Stock (NYSE:ZYME)

Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a human epidermal growth factor receptor 2 (HER2) that is in Phase 1, Phase 2, and Phase 3 clinical trials, including certain ongoing pivotal clinical trials; and zanidatamab zovodotin, a HER2 -targeted antibody-drug conjugate that is in Phase 2 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors. It also develops a pipeline of preclinical product candidates and discovery-stage programs in oncology, including immuno-oncology agents and other therapeutic areas. Zymeworks Inc. has strategic partnerships and collaborations with BeiGene, Ltd.; Celgene Corporation; Celgene Alpine Investment Co. LLC; GlaxoSmithKline Intellectual Property Development Limited; Daiichi Sankyo Co., Ltd.; Janssen Biotech, Inc.; LEO Pharma A/S; Iconic Therapeutics, Inc.; Merck Sharp & Dohme Research GmbH; and Atreca, Inc. Zymeworks Inc. was incorporated in 2003 and is based in Middletown, Delaware.

ZYME Stock Price History

ZYME Stock News Headlines

Tiny Biotech Stock Wins $75 Billion Patent
A little-known biotech has been quietly working on revolutionary treatments for neurodegenerative diseases. Most people have never heard of them... but those in the know have been taking notice. Jeff Bezos cut them a check for $130 million. Fidelity Biosciences for a further $217 million. They've even had several collaborative partnerships with much larger companies like Biogen, Sanofi, and Takeda.
Tiny Biotech Stock Wins $75 Billion Patent
A little-known biotech has been quietly working on revolutionary treatments for neurodegenerative diseases. Most people have never heard of them... but those in the know have been taking notice. Jeff Bezos cut them a check for $130 million. Fidelity Biosciences for a further $217 million. They've even had several collaborative partnerships with much larger companies like Biogen, Sanofi, and Takeda.
Analysts’ Top Healthcare Picks: Zymeworks (ZYME), 89bio (ETNB)
Zymeworks Q4 2023 Earnings Preview
ZYME Apr 2024 7.500 call
See More Headlines
Receive ZYME Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Zymeworks and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/06/2024
Today
4/19/2024
Next Earnings (Confirmed)
5/02/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Previous Symbol
NASDAQ:ZYME
Employees
272
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$15.00
High Stock Price Target
$19.00
Low Stock Price Target
$8.00
Potential Upside/Downside
+69.5%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
1 Analysts

Profitability

Net Income
$-118,670,000.00
Net Margins
-156.12%
Pretax Margin
-156.87%

Debt

Sales & Book Value

Annual Sales
$76.01 million
Book Value
$6.63 per share

Miscellaneous

Free Float
69,707,000
Market Cap
$624.54 million
Optionable
Optionable
Beta
1.14
Beginner's Guide to Pot Stock Investing Cover

Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.

Get This Free Report

Key Executives

  • Mr. Kenneth H. Galbraith C.A. (Age 61)
    CEO & Chairman of the Board
    Comp: $1.04M
  • Dr. Christopher Astle Ph.D. (Age 43)
    Senior VP & CFO
    Comp: $682.22k
  • Dr. Paul Moore Ph.D. (Age 56)
    Chief Scientific Officer
    Comp: $872.67k
  • Mr. Mark Hollywood (Age 54)
    Executive VP and Head of Technical & Manufacturing Operations
  • Mr. Daniel Dex J.D.
    Ph.D., Senior VP, Corporate Secretary & General Counsel
  • Diana Papove
    Senior Manager of Corporate Communications
  • Dr. Lindsey Foulkes B.Sc.
    Ph.D., Vice President of Corporate Development
  • Ms. Laura O'Connor
    Vice President of Human Resources & DEI
  • Dr. Jeffrey Smith M.D.
    Executive VP & Chief Medical Officer
  • Dr. Josemund Menezes MBBS
    Managing Director of Early-Stage Development for Asia Pacific

ZYME Stock Analysis - Frequently Asked Questions

Should I buy or sell Zymeworks stock right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Zymeworks in the last year. There are currently 1 hold rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" ZYME shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ZYME, but not buy additional shares or sell existing shares.
View ZYME analyst ratings
or view top-rated stocks.

What is Zymeworks' stock price target for 2024?

1 analysts have issued 12-month target prices for Zymeworks' shares. Their ZYME share price targets range from $8.00 to $19.00. On average, they expect the company's share price to reach $15.00 in the next twelve months. This suggests a possible upside of 69.5% from the stock's current price.
View analysts price targets for ZYME
or view top-rated stocks among Wall Street analysts.

How have ZYME shares performed in 2024?

Zymeworks' stock was trading at $10.39 at the start of the year. Since then, ZYME shares have decreased by 14.8% and is now trading at $8.85.
View the best growth stocks for 2024 here
.

When is Zymeworks' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024.
View our ZYME earnings forecast
.

How can I listen to Zymeworks' earnings call?

Zymeworks will be holding an earnings conference call on Thursday, May 2nd at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link.

How were Zymeworks' earnings last quarter?

Zymeworks Inc. (NYSE:ZYME) issued its quarterly earnings results on Wednesday, March, 6th. The company reported ($0.20) earnings per share for the quarter, topping the consensus estimate of ($0.39) by $0.19. The firm had revenue of $16.93 million for the quarter, compared to the consensus estimate of $18.32 million. Zymeworks had a negative net margin of 156.12% and a negative trailing twelve-month return on equity of 26.20%.

What ETF holds Zymeworks' stock?

Invesco Russell 2000 Dynamic Multifactor ETF holds 165,345 shares of ZYME stock, representing 0.41% of its portfolio.

What is Ali Tehrani's approval rating as Zymeworks' CEO?

9 employees have rated Zymeworks Chief Executive Officer Ali Tehrani on Glassdoor.com. Ali Tehrani has an approval rating of 100% among the company's employees. This puts Ali Tehrani in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 86.0% of employees surveyed would recommend working at Zymeworks to a friend.

What other stocks do shareholders of Zymeworks own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Zymeworks investors own include Advanced Micro Devices (AMD), Gilead Sciences (GILD), Just Energy Group (JE), NVIDIA (NVDA), Just Energy Group (JE), PayPal (PYPL), Alibaba Group (BABA), Cronos Group (CRON), CRISPR Therapeutics (CRSP) and Tesla (TSLA).

When did Zymeworks IPO?

Zymeworks (ZYME) raised $65 million in an IPO on Friday, April 28th 2017. The company issued 4,500,000 shares at a price of $13.00-$16.00 per share. Citigroup, Barclays, Wells Fargo Securities and Canaccord Genuity acted as the underwriters for the IPO and Cormark Securities was co-manager.

Who are Zymeworks' major shareholders?

Zymeworks' stock is owned by a variety of retail and institutional investors. Top institutional investors include Allspring Global Investments Holdings LLC (0.20%) and AlphaMark Advisors LLC (0.00%). Insiders that own company stock include Ali Tehrani, Christopher Astle, Ecor1 Capital, Llc, Kenneth Galbraith, Neil A Klompas, Neil Josephson and Paul Andrew Moore.
View institutional ownership trends
.

How do I buy shares of Zymeworks?

Shares of ZYME stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NYSE:ZYME) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners